antiVEGFterapier

Anti-VEGF therapies are a class of medications used to treat various eye conditions that cause abnormal blood vessel growth. These therapies work by targeting and inhibiting Vascular Endothelial Growth Factor (VEGF), a protein that plays a crucial role in the development of new blood vessels. In certain diseases, excessive VEGF production leads to the formation of fragile and leaky blood vessels in the retina, causing vision loss.

The primary application of anti-VEGF therapies is in the treatment of wet age-related macular degeneration (AMD). In this condition, abnormal blood vessels grow under the macula, the central part of the retina responsible for sharp, detailed vision. By blocking VEGF, these therapies can reduce leakage from these abnormal vessels, prevent further growth, and in many cases, improve or stabilize vision.

Other conditions treated with anti-VEGF agents include diabetic retinopathy, a complication of diabetes that can damage the blood vessels in the retina, and retinal vein occlusions, where a blockage in a retinal vein leads to swelling and vision impairment. The medications are typically administered via intravitreal injections, meaning they are injected directly into the vitreous humor of the eye. While generally safe and effective, potential side effects can include eye pain, increased intraocular pressure, and, rarely, more serious complications like infection or retinal detachment. Regular monitoring by an ophthalmologist is essential for patients undergoing anti-VEGF treatment.